Omeros swings to FY25 net loss of $3.4 million; cash and short-term investments rise to $172 million

Reuters04-01

Omeros swings to FY25 net loss of $3.4 million; cash and short-term investments rise to $172 million

Omeros posted Q4 2025 net income of USD 87 million, swinging from a loss a year earlier, as it booked a USD 238 million gain tied to the Novo Nordisk zaltenibart transaction.
Operating loss narrowed to USD 29 million for the quarter from USD 33 million a year earlier.
Cash and short-term investments totaled USD 172 million at year-end, while total debt fell 47% to USD 88 million.
FDA cleared YARTEMLEA for TA-TMA patients ages two and older, with U.S. commercial distribution starting in January 2026.
CEO Gregory A. Demopulos said the YARTEMLEA launch is underway, with Omeros targeting positive cash flow in 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Omeros Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20260331858919) on March 31, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2624537578?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-01 04:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2624537578","market":"nz","top_or_hot":-1,"title":"Omeros swings to FY25 net loss of $3.4 million; cash and short-term investments rise to $172 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Omeros swings to FY25 net loss of $3.4 million; cash and short-term investments rise to $172 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Omeros posted Q4 2025 net income of USD 87 million, swinging from a loss a year earlier, as it booked a USD 238 million gain tied to the <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> zaltenibart transaction.\n        </li>\n<li>\n          Operating loss narrowed to USD 29 million for the quarter from USD 33 million a year earlier.\n        </li>\n<li>\n          Cash and short-term investments totaled USD 172 million at year-end, while total debt fell 47% to USD 88 million.\n        </li>\n<li>\n          FDA cleared YARTEMLEA for TA-TMA patients ages two and older, with U.S. commercial distribution starting in January 2026.\n        </li>\n<li>\n          CEO Gregory A. Demopulos said the YARTEMLEA launch is underway, with Omeros targeting positive cash flow in 2027.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Omeros Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20260331858919) on March 31, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Omeros swings to FY25 net loss of $3.4 million; cash and short-term investments rise to $172 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOmeros swings to FY25 net loss of $3.4 million; cash and short-term investments rise to $172 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-04-01 04:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Omeros swings to FY25 net loss of $3.4 million; cash and short-term investments rise to $172 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Omeros posted Q4 2025 net income of USD 87 million, swinging from a loss a year earlier, as it booked a USD 238 million gain tied to the <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> zaltenibart transaction.\n        </li>\n<li>\n          Operating loss narrowed to USD 29 million for the quarter from USD 33 million a year earlier.\n        </li>\n<li>\n          Cash and short-term investments totaled USD 172 million at year-end, while total debt fell 47% to USD 88 million.\n        </li>\n<li>\n          FDA cleared YARTEMLEA for TA-TMA patients ages two and older, with U.S. commercial distribution starting in January 2026.\n        </li>\n<li>\n          CEO Gregory A. Demopulos said the YARTEMLEA launch is underway, with Omeros targeting positive cash flow in 2027.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Omeros Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20260331858919) on March 31, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDL918k15:1","article_id":"2624537578","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2624537578","pubTimestamp":1774987509,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Omeros posted Q4 2025 net income of USD 87 million, swinging from a loss a year earlier, as it booked a USD 238 million gain tied to the Novo Nordisk zaltenibart transaction.Operating loss narrowed to USD 29 million for the quarter from USD 33 million a year earlier.Cash and short-term investments totaled USD 172 million at year-end, while total debt fell 47% to USD 88 million.FDA cleared YARTEMLEA for TA-TMA patients ages two and older, with U.S. commercial distribution starting in January 2026.CEO Gregory A. Demopulos said the YARTEMLEA launch is underway, with Omeros targeting positive cash flow in 2027.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Omeros Corporation published the original content used to generate this news brief ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","OMER":"奥麦罗制药"},"translate_title":"Omeros 2025财年净亏损为340万美元；现金和短期投资增至1.72亿美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OMER":0.9},"content_text":"Omeros swings to FY25 net loss of $3.4 million; cash and short-term investments rise to $172 million\n    \n\n\n          Omeros posted Q4 2025 net income of USD 87 million, swinging from a loss a year earlier, as it booked a USD 238 million gain tied to the Novo Nordisk zaltenibart transaction.\n        \n\n          Operating loss narrowed to USD 29 million for the quarter from USD 33 million a year earlier.\n        \n\n          Cash and short-term investments totaled USD 172 million at year-end, while total debt fell 47% to USD 88 million.\n        \n\n          FDA cleared YARTEMLEA for TA-TMA patients ages two and older, with U.S. commercial distribution starting in January 2026.\n        \n\n          CEO Gregory A. Demopulos said the YARTEMLEA launch is underway, with Omeros targeting positive cash flow in 2027.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Omeros Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20260331858919) on March 31, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2624537578","isCrawlerRequest":true}